Sanofi, Denali Launch $1B+ Alliance to Develop RIPK1 Inhibitors for Neurological, Inflammatory Diseases

Sanofi will partner with Denali Therapeutics to develop its receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor candidates as treatments for neurological and systemic inflammatory diseases, Denali said, through a collaboration that could generate more than $1.125 billion for the South San Francisco, CA, biotech.Denali’s RIPK1 inhibitor pipeline consists of candidates designed to target RIPK1, a signaling protein in the TNF receptor pathway that regulates inflammation a